OpenLB
Open Library of Bioscience
Advanced Search
Immunologic research
Dec, 2012;54 (1-3): 140-51.

Diverse immune evasion strategies by human cytomegalovirus.

Vanessa Noriega, Veronika Redmann, Thomas Gardner, Domenico Tortorella
Author Information
  1. Vanessa Noriega: Department of Microbiology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1124, New York, NY 10029, USA.
PMID: 22454101 DOI: 10.1007/s12026-012-8304-8

Abstract

Members of the Herpesviridae family have the capacity to undergo both lytic and latent infection to establish a lifelong relationship with their host. Following primary infection, human cytomegalovirus (HCMV) can persist as a subclinical, recurrent infection for the lifetime of an individual. This quiescent portion of its life cycle is termed latency and is associated with periodic bouts of reactivation during times of immunosuppression, inflammation, or stress. In order to exist indefinitely and establish infection, HCMV encodes a multitude of immune modulatory mechanisms devoted to escaping the host antiviral response. HCMV has become a paradigm for studies of viral immune evasion of antigen presentation by both major histocompatibility complex (MHC) class I and II molecules. By restricting the presentation of viral antigens during both productive and latent infection, HCMV limits elimination by the human immune system. This review will focus on understanding how the virus manipulates the pathways of antigen presentation in order to modulate the host response to infection.

References

  1. J Biol Chem. 2008 Feb 15;283(7):4031-43 [PMID: 18086679]
  2. Nat Immunol. 2008 May;9(5):495-502 [PMID: 18425106]
  3. Nat Rev Immunol. 2010 Jun;10(6):403-14 [PMID: 20498667]
  4. Immunity. 2011 Aug 26;35(2):161-8 [PMID: 21867926]
  5. J Virol. 1994 Jun;68(6):4017-21 [PMID: 8189535]
  6. Science. 2010 Apr 2;328(5974):102-6 [PMID: 20360110]
  7. Nature. 2001 Dec 6;414(6864):652-6 [PMID: 11740563]
  8. J Gen Virol. 1992 Sep;73 ( Pt 9):2395-403 [PMID: 1328494]
  9. Eur J Cell Biol. 1991 Apr;54(2):299-304 [PMID: 1652444]
  10. Nat Immunol. 2002 Dec;3(12):1169-76 [PMID: 12436109]
  11. Blood. 1999 Jan 1;93(1):394-8 [PMID: 9864186]
  12. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6794-9 [PMID: 11391001]
  13. J Immunol. 2003 Dec 15;171(12):6757-65 [PMID: 14662880]
  14. J Virol. 2002 Nov;76(21):10929-41 [PMID: 12368336]
  15. J Clin Virol. 2008 Mar;41(3):180-5 [PMID: 18164651]
  16. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10990-5 [PMID: 8855296]
  17. J Innate Immun. 2012;4(1):6-15 [PMID: 22086146]
  18. Immunology. 2011 Aug;133(4):409-19 [PMID: 21627652]
  19. Curr Top Microbiol Immunol. 2008;325:85-100 [PMID: 18637501]
  20. Virology. 1993 Apr;193(2):834-41 [PMID: 8384757]
  21. Nature. 1998 Feb 19;391(6669):795-9 [PMID: 9486650]
  22. Future Microbiol. 2010 Jun;5(6):883-900 [PMID: 20521934]
  23. Virology. 2003 Oct 25;315(2):353-61 [PMID: 14585338]
  24. APMIS. 2009 May;117(5-6):413-26 [PMID: 19400865]
  25. Science. 2010 Jan 15;327(5963):291-5 [PMID: 20075244]
  26. J Virol. 2006 Jan;80(2):710-22 [PMID: 16378974]
  27. Nat Rev Immunol. 2011 Nov 11;11(12):823-36 [PMID: 22076556]
  28. J Cell Biol. 2006 Oct 23;175(2):261-70 [PMID: 17043138]
  29. J Virol. 1995 Aug;69(8):4830-41 [PMID: 7609050]
  30. Adv Immunol. 2011;109:125-57 [PMID: 21569914]
  31. J Virol. 1997 Feb;71(2):1246-55 [PMID: 8995648]
  32. J Virol. 2008 Jan;82(1):60-70 [PMID: 17942555]
  33. J Virol. 2004 Feb;78(3):1440-7 [PMID: 14722299]
  34. J Virol. 2006 Jan;80(2):951-63 [PMID: 16378997]
  35. J Gen Virol. 2004 May;85(Pt 5):1301-1312 [PMID: 15105547]
  36. J Virol. 2011 May;85(10):5150-8 [PMID: 21367908]
  37. Rev Infect Dis. 1983 Mar-Apr;5(2):205-15 [PMID: 6302813]
  38. J Exp Med. 1992 Sep 1;176(3):729-38 [PMID: 1324970]
  39. Nature. 1988 Jan 21;331(6153):269-72 [PMID: 2827039]
  40. Semin Cell Dev Biol. 2010 Jul;21(5):512-9 [PMID: 20044014]
  41. EMBO J. 2008 Jan 9;27(1):1-5 [PMID: 18046453]
  42. Science. 2011 Nov 25;334(6059):1086-90 [PMID: 22116878]
  43. Immunol Lett. 2011 Aug 30;138(2):97-103 [PMID: 21324342]
  44. J Virol. 2002 May;76(10):5043-50 [PMID: 11967320]
  45. J Virol. 2002 Feb;76(3):1285-92 [PMID: 11773404]
  46. J Virol. 2004 Aug;78(16):8720-31 [PMID: 15280480]
  47. Blood. 2002 Oct 15;100(8):2867-73 [PMID: 12351397]
  48. J Virol. 1993 Jun;67(6):3461-9 [PMID: 8388509]
  49. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204 [PMID: 9560253]
  50. J Gen Virol. 2007 May;88(Pt 5):1429-1439 [PMID: 17412970]
  51. Mol Biol Cell. 2003 Sep;14(9):3690-8 [PMID: 12972557]
  52. Annu Rev Immunol. 2000;18:861-926 [PMID: 10837078]
  53. Nature. 1996 Dec 5;384(6608):432-8 [PMID: 8945469]
  54. J Virol. 1999 Mar;73(3):2181-92 [PMID: 9971801]
  55. Immunity. 1997 May;6(5):613-21 [PMID: 9175839]
  56. Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12325-30 [PMID: 18711132]
  57. Nature. 1996 Oct 24;383(6602):720-2 [PMID: 8878482]
  58. J Biol Chem. 2010 Oct 15;285(42):32352-9 [PMID: 20702414]
  59. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1695-700 [PMID: 10677520]
  60. Nat Rev Mol Cell Biol. 2008 Dec;9(12):944-57 [PMID: 19002207]
  61. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S468-76 [PMID: 2847283]
  62. Nature. 2004 Jun 24;429(6994):841-7 [PMID: 15215856]
  63. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8516-21 [PMID: 10411907]
  64. Nat Immunol. 2011 Jun;12(6):485-91 [PMID: 21739671]
  65. J Pediatr. 1985 Dec;107(6):953-6 [PMID: 2999369]
  66. Eur J Immunol. 2003 Jun;33(6):1707-16 [PMID: 12778489]
  67. Virology. 1993 Apr;193(2):727-36 [PMID: 8384753]
  68. Nat Med. 1999 Sep;5(9):1039-43 [PMID: 10470081]
  69. Blood. 2011 Dec 22;118(26):6783-92 [PMID: 22031867]
  70. Eur J Immunol. 2001 May;31(5):1428-37 [PMID: 11465099]
  71. J Gen Virol. 2005 Feb;86(Pt 2):275-284 [PMID: 15659746]
  72. Nat Immunol. 2002 Nov;3(11):1006-12 [PMID: 12407408]
  73. J Biol Chem. 2006 Jul 14;281(28):19395-406 [PMID: 16687410]
  74. J Intern Med. 2006 Mar;259(3):219-46 [PMID: 16476101]
  75. Eur J Immunol. 2003 Jan;33(1):194-203 [PMID: 12594848]
  76. Curr Top Microbiol Immunol. 2008;325:187-204 [PMID: 18637507]
  77. PLoS Pathog. 2008 Aug 08;4(8):e1000123 [PMID: 18688275]
  78. Nature. 2004 Jun 24;429(6994):834-40 [PMID: 15215855]
  79. J Virol. 2002 Nov;76(22):11753-6 [PMID: 12388737]
  80. J Gen Virol. 2008 May;89(Pt 5):1122-1130 [PMID: 18420789]
  81. J Virol. 1999 Jun;73(6):4806-12 [PMID: 10233941]
  82. J Virol. 2008 Apr;82(7):3271-82 [PMID: 18199642]
  83. J Virol. 2003 Feb;77(3):2147-56 [PMID: 12525649]
  84. BMJ. 1989 Oct 7;299(6704):897-8 [PMID: 2555001]
  85. J Virol. 2002 May;76(10):5147-55 [PMID: 11967330]
  86. J Immunol. 2002 Apr 1;168(7):3464-9 [PMID: 11907106]
  87. Rev Infect Dis. 1983 Nov-Dec;5(6):977-93 [PMID: 6318291]
  88. J Immunol. 2004 Sep 1;173(5):3383-91 [PMID: 15322202]
  89. J Exp Med. 1998 Aug 3;188(3):497-503 [PMID: 9687527]
  90. Transfusion. 1989 Nov-Dec;29(9):757-60 [PMID: 2555938]
  91. J Exp Med. 2010 Aug 30;207(9):2033-41 [PMID: 20713594]
  92. J Virol. 2004 Sep;78(18):10023-33 [PMID: 15331735]
  93. EMBO J. 2001 Feb 1;20(3):387-96 [PMID: 11157746]
  94. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3937-42 [PMID: 9520471]
  95. J Biol Chem. 2001 Dec 21;276(51):48031-9 [PMID: 11606590]
  96. J Virol. 2003 Aug;77(15):8541-7 [PMID: 12857923]
  97. Immunity. 1997 Aug;7(2):273-82 [PMID: 9285411]
  98. Virology. 2009 Aug 15;391(1):5-19 [PMID: 19570562]
  99. J Pediatr. 1981 Feb;98(2):281-7 [PMID: 6257877]
  100. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16255-60 [PMID: 12456880]
  101. Nature. 2006 Jun 15;441(7095):894-7 [PMID: 16738546]
  102. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18153-8 [PMID: 16319222]
  103. Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6904-9 [PMID: 9192664]
  104. J Virol. 1997 Apr;71(4):2970-9 [PMID: 9060656]
  105. Virus Res. 2011 May;157(2):161-74 [PMID: 20933556]
  106. J Virol. 2009 Feb;83(3):1359-67 [PMID: 19004944]
  107. J Virol. 2003 Oct;77(20):10943-56 [PMID: 14512544]
  108. Immunity. 2004 Jan;20(1):71-85 [PMID: 14738766]
  109. J Virol. 1989 Mar;63(3):1435-40 [PMID: 2536844]
  110. Blood. 2006 Mar 1;107(5):2022-9 [PMID: 16269620]
  111. J Virol. 1996 Jan;70(1):78-83 [PMID: 8523595]
  112. Rev Infect Dis. 1990 Sep-Oct;12 Suppl 7:S754-66 [PMID: 2173105]
  113. Virology. 2002 Sep 15;301(1):32-42 [PMID: 12359444]
  114. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11327-33 [PMID: 8876135]
  115. Mol Biol Cell. 2001 Aug;12(8):2546-55 [PMID: 11514634]
  116. J Leukoc Biol. 2006 May;79(5):932-40 [PMID: 16501053]
  117. J Intern Med. 2010 May;267(5):483-501 [PMID: 20433576]
  118. J Clin Virol. 2008 Mar;41(3):206-12 [PMID: 18069056]
  119. J Gen Virol. 1991 Sep;72 ( Pt 9):2059-64 [PMID: 1654370]
  120. J Gen Virol. 2006 Sep;87(Pt 9):2451-2460 [PMID: 16894182]
  121. J Exp Med. 1998 Mar 2;187(5):813-8 [PMID: 9480992]
  122. Microbiol Mol Biol Rev. 2008 Jun;72(2):249-65, table of contents [PMID: 18535146]
  123. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4140-5 [PMID: 15738399]
  124. J Virol. 2011 Dec;85(23):12750-8 [PMID: 21937636]
  125. Blood. 2009 Nov 5;114(19):4128-37 [PMID: 19706889]
  126. J Biol Chem. 2006 Jul 28;281(30):20910-20919 [PMID: 16731524]
  127. J Gen Virol. 1996 Dec;77 ( Pt 12):3099-102 [PMID: 9000102]
  128. J Gen Virol. 2006 Jul;87(Pt 7):1763-1779 [PMID: 16760381]
  129. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11439-44 [PMID: 12972646]
  130. Blood. 2003 Jun 15;101(12):4870-7 [PMID: 12609847]
  131. J Allergy Clin Immunol. 2010 May;125(5):985-92 [PMID: 20392481]
  132. J Virol. 1999 Feb;73(2):1468-78 [PMID: 9882353]
  133. J Virol. 2004 Aug;78(15):8333-41 [PMID: 15254205]
  134. J Virol. 2011 Nov;85(22):11638-45 [PMID: 21880752]
  135. Nat Immunol. 2011 Sep 04;12(10):984-91 [PMID: 21892175]
  136. J Virol. 2001 Jun;75(11):5197-204 [PMID: 11333901]
  137. Cell. 1996 Mar 8;84(5):769-79 [PMID: 8625414]
  138. J Virol. 1998 Apr;72(4):3321-9 [PMID: 9525659]
  139. J Immunol. 1993 Nov 1;151(9):4455-64 [PMID: 8409412]
  140. J Immunol. 2000 Jan 15;164(2):805-11 [PMID: 10623826]
  141. J Virol. 2005 Mar;79(5):2869-79 [PMID: 15709006]
  142. Annu Rev Cell Dev Biol. 1997;13:669-95 [PMID: 9442884]

Grants

  1. T32-AI07647/NIAID NIH HHS
  2. T32-AI078892/NIAID NIH HHS

MeSH Term

Antigen Presentation
Cytomegalovirus
Cytomegalovirus Infections
Histocompatibility Antigens Class I
Histocompatibility Antigens Class II
Humans
Immune Evasion
Virus Latency

Chemicals

Histocompatibility Antigens Class I
Histocompatibility Antigens Class II
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 11

Word Cloud

Created with Highcharts 10.0.0infectionHCMVimmunehosthumanpresentationlatentestablishcytomegalovirusorderresponseviralevasionantigenMembersHerpesviridaefamilycapacityundergolyticlifelongrelationshipFollowingprimarycanpersistsubclinicalrecurrentlifetimeindividualquiescentportionlifecycletermedlatencyassociatedperiodicboutsreactivationtimesimmunosuppressioninflammationstressexistindefinitelyencodesmultitudemodulatorymechanismsdevotedescapingantiviralbecomeparadigmstudiesmajorhistocompatibilitycomplexMHCclassIImoleculesrestrictingantigensproductivelimitseliminationsystemreviewwillfocusunderstandingvirusmanipulatespathwaysmodulateDiversestrategies

Similar Articles

Cited By (68)